OliX said Monday that it will expand research and development of next-generation obesity treatments based on its proprietary adipose tissue-targeting RNA interference (RNAi) platform (OASIS-Adipose), in line with global trends in obesity drug development observed at 'BIO-Europe 2026,' held in Cologne, Germany, from the 9th to the 11th.
OliX explained that it confirmed at this year's BIO-Europe that global obesity treatment development is expanding significantly in two directions.
One is a combination therapy strategy that combines new drugs with different mechanisms of action with existing GLP-1 (glucagon-like peptide-1) class treatments to improve therapeutic efficacy.
The other is the development of non-incretin new drugs with mechanisms of action differentiated from the 'incretin' class. It noted that, amid growing interest in new mechanisms of action, pathways related to 'ALK7' and 'INHBE,' which are involved in metabolic regulation of adipose tissue, are also attracting attention as key research targets for developing next-generation obesity treatments.
Such market changes can be seen in technology transfer cases by global pharmaceutical companies. In fact, in October last year, Roche signed a global exclusive technology transfer agreement worth up to $1.16 billion (approximately 1.5476 trillion won) for Rona Therapeutics' ALK7-targeting RNAi obesity treatment.
To respond to such market demand, OliX is strengthening its research and development capabilities centered on its proprietary adipose tissue-targeting RNAi platform.
OliX's 'OASIS-Adipose' is a platform designed to selectively inhibit the expression of specific genes within adipose tissue. It allows for the development of new drugs with mechanisms of action differentiated from existing incretin class treatments, as well as expansion into various new targets and combination therapies.
OliX's flagship program, the ALK7-targeting obesity treatment 'OLX501A,' confirmed its efficacy in reducing visceral fat in previously conducted non-human primate (NHP) trials.
It also demonstrated body composition improvement effects in mouse models. The company is developing it with the goal of filing an Investigational New Drug (IND) application in the first half of next year.
OliX's OLX501A is attracting attention as a pipeline that addresses muscle loss, which is cited as a limitation of currently marketed obesity treatments.
It is described as a substance that can selectively reduce body fat while preserving muscle mass. The company is continuing discussions on global collaborations ahead of entering Phase 1 clinical trials.
OliX is also advancing research on combination therapies with incretin class treatments. Previously, in an obese mouse model, OliX confirmed the potential for reduced body fat and mitigated loss of lean body mass when OLX501A was administered in combination with tirzepatide, a GLP-1/GIP dual agonist.
Based on this, it is conducting follow-up studies to secure non-human primate trial data for the combination therapy by early next year.
The discovery of new adipose tissue targets is also underway. OliX confirmed gene expression inhibition and efficacy in reducing weight and body fat in existing obese mouse models for a new target (Target X) other than ALK7.
It is now verifying the potential for further efficacy improvements. Additionally, the company has developed 'OASIS-D-Adipose' technology, which simultaneously inhibits two target genes in adipose tissue, with a strategy to build a next-generation obesity treatment portfolio that goes beyond single targets.
Lee Dong-gi, CEO of OliX, stated, "We confirmed at this year's BIO-Europe that interest is growing in new mechanisms of action and combination therapies in the next-generation obesity treatment market."
He added, "In particular, these market changes align with the research and development direction OliX is pursuing based on its adipose tissue-targeting RNAi technology."
He said the company conducted in-depth discussions with various potential partners regarding obesity treatment R&D strategies and collaboration possibilities.
"We will actively engage in follow-up discussions to ensure these talks lead to tangible outcomes in technology transfer and partnerships," he said.